R Squared’s Corvus Pharmaceuticals CRVS Stock Holding History

R Squared’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-290	Closed	-$1.55K	–	573
2024 Q4	$1.55K	Buy	+290	New	+$2.17K	﹤0.01%	1483

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

R Squared's CRVS Position: Q1 2025 in Review

R Squared sold out of Corvus Pharmaceuticals (CRVS) in Q1 2025, closing a stake of 290 shares — an estimated $1.55K sold.

R Squared first reported a position in CRVS in Q4 2024 and held it in 1 quarter. The position peaked at $1.55K in Q4 2024. 88 funds tracked by Wall St. Rank hold CRVS as of Q1 2025.

R Squared reported no remaining Corvus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 290 Corvus Pharmaceuticals shares in Q1 2025, an estimated $1.55K.
R Squared first reported a position in Corvus Pharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's Corvus Pharmaceuticals position peaked at $1.55K in Q4 2024.
88 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.